Trial Profile
Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Rotavirus W179-9 vaccine (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 07 Mar 2018 Results (n=109) assessing intestinal damage and inflammation in perinatally HIV-1-infected african infants, were presented at the 25th Conference on Retroviruses and Opportunistic Infections.
- 16 Feb 2017 Results of a secondary analysis (n=89) associating HIV status and rotavirus vaccine with B and T cell subsets, presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 17 Feb 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.